Browse > Home / Pharmacy Industry News / Micromet Reports Interim Data From Phase 1 Study Of BiTE Antibody MT110 For The Treatment Of Solid Tumors

Micromet Reports Interim Data From Phase 1 Study Of BiTE Antibody MT110 For The Treatment Of Solid Tumors

September 22, 2009

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented in the beginning mean-time data from a phasis 1 dose-escalation clinical study for BiTE antibody MT110, the in the first place T-cell engaging antibody for the manipulation of solid tumors. The interim data(1) were presented at the Multidisciplinary Congress of the European Cancer Organisation (ECCO) and 34th meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany. MT110 is designed to direct the patients’ own T cells against cancer cells that precise the epithelial cell adhesion molecule (EpCAM).

To have being reckoned, 20 patients with late-stage lung or gastrointestinal cancers have been treated with MT110. The starting dose in this phase 1 disagreeable lot escalation trial was 1 microgram for patient per day. Results from doses up to 12 micrograms in opposition to patient by means of day were reported. MT110 is administered by continuous intravenous infusion for a minimum of four weeks with the preference of adscititious treatment cycles until disease passage. No greatest tolerated drench has been reached and dose escalation is ongoing. MT110 is well tolerated through not one stage 3 or 4 clinical events related to MT110 therapy observed so far. The most usual adverse events cognate to MT110 method of treating were mild pyrexia and fatigue. Laboratory analysis of all patients revealed an early clinically asymptomatic greaten of liver enzymes that normalized after several days under continued treatment. Other laboratory abnormalities included transient lymphopenia. No cytokine release syndrome, pancreatitis or immune replication to MT110 was observed. At the dose levels pure to date, disease stabilization was seen in 7 of 18 evaluable patients in the rear of the first cycle of method of treating, and dose escalation continues.

“We are very encouraged by the tolerability of MT110 observed in this heavily pre-treated population of cancer patients and look forward to updating our results as we continue to become greater the dose,” commented Prof. Walter Fiedler from the University Hospital of Hamburg-Eppendorf, Germany, and leader investigator of the weigh.

“The interim phase 1 results and activity of MT110 at the current dose level are the kind of we expected based on our preclinical premises,” commented Christian Itin, CEO of Micromet. “We are at once looking in advance to exploring the clinical activity of MT110 at higher dose levels.”

MT110 is the assist BiTE antibody undergoing clinical investigation. Micromet also has ongoing trials despite blinatumomab (MT103), including a aspect 2 tribulation for severe lymphoblastic leukemia (ALL) and a phase 1 trial according to non-Hodgkin’session lymphoma.

(1) Fiedler, W. et al. (2009) Safety and pharmacology of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients by metastatic colorectal, gastric, or lung cancer. ECCO/ESMO Meeting, Berlin, Abstract No. 1254

About BiTE Antibodies

BiTE(R) antibodies are the first T cell engaging antibodies to afford clinical benefit in cancer patients, representing a new approach to cancer therapy. While previous attempts obtain shown the potential for the carcass’s solitary abode; squalid destroying T cells to discourse on cancer, these therapies have been hampered by the cancer cells’ ability to avoid recognition by T cells. BiTE antibodies engage T cells to attack cancer cells anywhere in the body.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies with respect to the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes fresh antibodies generated with its see preprinter BiTE(R) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet’s BiTE antibodies and three of its customary antibodies are currently in clinical trials. Micromet’s preclinical product pipeline includes exclusive novel BiTE antibodies generated by its proprietary BiTE antibody platform technology. Micromet’s collaboration partners include Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could inducement actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the safety, competency, and intended utilization of Micromet’s BiTE antibody MT110 and other product candidates, the conduct, timing and results of hereafter clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words “ongoing,” “may,” “will,” “believes,” “potential,” “expects,” “plans,” “anticipates,” “intends,” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause not merely supposed or fancied results to be unlike materially from a single one future results expressed or implied by means of any forward-looking statements include the hazard that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical apply the mind to or clinical ordeal, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further separation of preclinical or clinical trial data, the risk that we or our collaborators direction not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet forfeiting life requirements, and the risks associated by reliance on collaborators, including Bayer Schering Pharma, MedImmune, Merck Serono, TRACON and Nycomed, for the funding or escort of to a greater distance development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet’s Quarterly Report on Form 10-Q instead of the financial separate into parts ended June 30, 2009, filed with the SEC on August 6, 2009, as well as other filings by the company with the SEC.

Source: Micromet, Inc.

Written by Samanta · Filed Under Pharmacy Industry News